The addiction of LUAD tumors harboring Nf1 mutations to glutamine made them susceptible to glutaminase and Psat1 inhibitors, a strategy that could potentially apply to additional cancers with alterations in the NF1–FAK1 pathway. This evidence concerns the gene GLS and cancer.